The Radiology Business Journal (11/6, Walter) reports that research suggests “developing electronic triggers to detect delays in follow-up of abnormal mammographic results offers healthcare providers with an ‘unprecedented opportunity to improve care.’” The findings were published in the Journal of the American College of Radiology.
Medscape (11/3, Nelson) reported that “last year, the French Minister for Health requested that the French National Cancer Institute organize a broad public and scientific consultation on breast cancer screening.” Although it is “still a work in progress, the subsequent report [pdf] issued in April 2017 called for multiple reforms and could be the beginning of a more personalized approach to breast cancer screening.” Medscape added, “In a Viewpoint article published online...in JAMA Internal Medicine, three experts summarize the reforms and offer some insight on how they differ from efforts in other countries.”
HealthDay (10/26, Preidt) reports that research indicates “knowing they’re at increased risk for breast cancer isn’t enough to persuade many women to get MRI screenings – even if they’re free.” The findings were presented at an American College of Surgeons meeting.
Aunt Minnie (10/30, Yee) reports that mammograms remain “the best tool for breast cancer screening” as compared to thermography. The FDA released a consumer health statement adding that although “it has received reports from physicians and patients that some healthcare facilities are providing information that misleads patients into thinking that thermography is a proven alternative to mammography,” the evidence shows that “thermography has not been shown to be effective as a standalone test for breast cancer screening or diagnosis for early-stage breast cancer, the FDA said in the statement.” Dr. Helen Barr, director of the Division of Mammography Quality Standards in the FDA’s Center for Devices and Radiological Health, said, “You should not rely solely on thermography for the screening or diagnosis of breast cancer.”
Aunt Minnie (11/1) reports that a new study in the Journal of the American College of Surgeons found that “surveillance is safe” for a type of high-risk breast “lesion called flat epithelial atypia” that is “typically treated surgically.” Researchers at Massachusetts General Hospital reviewed 208 patients’ medical records over a nine-year period. Senior author Dr. Constance Lehman said, “Surveillance, rather than surgery, is a good option for women with [flat epithelial atypia] lesions who do not have a genetic mutation and are not interested in chemoprevention.”